You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽隆藥業(002898.SZ):2020年度由盈轉虧 預虧5300萬元-7500萬元
格隆匯 01-28 21:01

格隆匯 1 月 28日丨賽隆藥業(002898.SZ)披露2020年年度業績預吿,預計2020年歸屬於上市公司股東的淨虧損5300萬元-7500萬元,上年同期盈利2748.32萬元;扣除非經常性損益後的淨虧損5343.88萬元-7543.88萬元,上年同期盈利1465.13萬元。業績變動原因如下:

1.2020年初新冠肺炎疫情爆發,同時由於公司門冬氨酸鳥氨酸注射液、注射用胸腺法新、阿加曲班注射液、注射用替加環素等獲批的新產品的市場導入需要較長週期,且繼續受國家重點監控合理用藥藥品目錄及地方輔助用藥目錄等多個醫藥政策的不利影響,公司營業收入較上年同期下降50%以上。

2.報吿期內公司研發費用投入約達2,655萬元,較上年同期增長50%以上。

3.報吿期內非經常性損益對利潤總額的影響金額約為43.88萬元,其中收到政府相關補助為245.97萬元,去年同期收到的政府補助為1346.65萬元,較上年同期下降1100.68萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account